CEL-SCI: Robert Watson
CEL-SCI has appointed Robert Watson to its Board of Directors.
Watson is currently the president of preparedness technology at Intermedix, and has held positions at NantHealth and Streamline Health.
He holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BA from Syracuse University.
CEL-SCI focuses on Phase III cancer immunotherapies – including its lead candidate Multikine –indicated to treat patients who are newly diagnosed with head and neck cancer, before they have received surgery, radiation and/or chemotherapy.
Watson told us he is joining the firm at an exciting time.
“As a ‘fresh’ set of eyes at the table, I hope to provide management with guidance to navigate the paths in front of us,” he told us.
Holiday plans?
Watson told us he plans to spend the holidays with his family.
